EP0271193A2 - Controlled release hydromorphone composition - Google Patents

Controlled release hydromorphone composition Download PDF

Info

Publication number
EP0271193A2
EP0271193A2 EP87309333A EP87309333A EP0271193A2 EP 0271193 A2 EP0271193 A2 EP 0271193A2 EP 87309333 A EP87309333 A EP 87309333A EP 87309333 A EP87309333 A EP 87309333A EP 0271193 A2 EP0271193 A2 EP 0271193A2
Authority
EP
European Patent Office
Prior art keywords
hydromorphone
weight
hours
dosage form
characterised
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP87309333A
Other languages
German (de)
French (fr)
Other versions
EP0271193A3 (en
EP0271193B1 (en
Inventor
Robert Stronech Goldie
Sandra Therese Antoinette Malkowska
Stewart Thomas Leslie
Ronald Brown Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euroceltique SA
Original Assignee
Euroceltique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to GB8626098 priority Critical
Priority to GB868626098A priority patent/GB8626098D0/en
Application filed by Euroceltique SA filed Critical Euroceltique SA
Priority claimed from AT87309333T external-priority patent/AT67933T/en
Publication of EP0271193A2 publication Critical patent/EP0271193A2/en
Publication of EP0271193A3 publication Critical patent/EP0271193A3/en
Publication of EP0271193B1 publication Critical patent/EP0271193B1/en
Application granted granted Critical
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10606640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0271193(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Anticipated expiration legal-status Critical
Application status is Expired - Lifetime legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Abstract

A solid controlled release, oral dosage form, the dosage form comprising a therapeutically effective amount of hydromorphone or a salt thereof in a matrix wherein the dissolution rate in vitro of the dosage form when measured by the USP Paddle Method at 100rpm in 900ml aqueous buffer (pH between 1.6 and 7.2) at 37°C is between 12.5% and 42.5% (by weight) hydromorphone released after 1 hour, between 25% and 55% (by weight) hydromorphone released after 2 hours, between 45% and 75% (by weight) hydromorphone released after 4 hours and between 55% and 85% (by weight) hydromorphone released after 6 hours, the in vitro release rate being independent of pH between pH 1.6 and 7.2 and chosen such that the peak plasma level of hydromorphone obtained in vivo occurs between 2 and 4 hours after administration of the dosage form.

Description

  • The present invention relates to a solid, controlled release, oral dosage form containing hydromorphone for use in the treatment of moderate to severe pain.
  • According to the present invention there is provided a solid, controlled release, oral dosage form, the dosage form comprising a therapeutically effective amount of hydromorphone or a salt thereof in a matrix wherein the dissolution rate in vitro of the dosage form, when measured by the USP Paddle Method at 100 rpm in 900 ml. aqueous buffer (pH between 1.6 and 7.2) at 37°C is between 12.5 and 42.5% (by wt) hydromorphone released after 1 hour, between 25 and 55% (by wt) hydromorphone released after 2 hours, between 45 and 75% (by wt) hydromorphone released after 4 hours and between 55 and 85% (by wt) hydromorphone released after 6 hours, the in vitro release rate being independent of pH between pH 1.6 and 7.2 and such that the peak plasma level of hydromorphone obtained in vitro occurs between 2 and 4 hours after administration of the dosage form. Preferably, the dosage form contains an analgesically effective amount of hydromorphone or a salt thereof.
  • USP Paddle Method is the Paddle Method described in US Pharmacopoeia XXI (1985).
  • In the present specification, "independent of pH" means that the difference, at any given time, between the amount of hydromorphone released at pH 1.6 and the amount released at any other pH up to, and including, pH 7.2 (when measured in vitro using the USP Paddle Method at 100rpm in 900ml aqueous buffer) is 10% (by weight) or less. The amounts released being, in all cases, a mean of at least three experiments.
  • In the present specificationn, "peak plasma level of hydromorphone obtained in vivo" refers to the maximum mean concentration of hydromorphone found in the plasma of at least six healthy volunteers, when (the volunteers are) subjected to a single dose, pharmacokinetic study.
  • Preferably the dissolution rate is between 17.5 and 37.5% (by wt) hydromorphone released after 1 hour, between 30 and 50% (by wt) after 2 hours, between 50 and 70% (by wt) after 4 hours and between 60 and 80% (by wt) after 6 hours. Most preferably, the dissolution rate is between 22.5 and 32.5% (by wt) hydromorphone released after 1 hour, between 35 and 45% (by wt) after 2 hours, between 55 and 65% (by wt) after 4 hours and between 65 and 75% (by wt) after 6 hours.
  • Preferably the peak plasma level of hydromorphone is obtained in vivo between 2.25 and 3.75 hours after administration of the dosage form.
  • When the hydromophone is administered as hydromorphone hydrochloride and the method of hydromophone is plasma analysis is a double antibody radioimmuniassay (as hereinafter described), the peak plasma level of hydromorphone (per ml. of plasma) is preferably between 0.5 x 10⁻⁶ and 2.0 x 10⁻⁶, most preferably between 0.5 x 10⁻⁶ and 1.5 x 10⁻⁶, of the amount of hydromorphone hydrochloride administered orally.
  • Thus, if 4mg of hydromorphone hydrochloride is administered the peak plasma level of hydromorphone is preferably between 2 and 8ngml⁻¹, especially between 2 and 6ngml⁻¹.
  • When hydromorphone base or a salt other than the hydrochloride is administered, the preferred ratio of drug. administered to peak plasma level of hydromorphone must be adjusted according to the molecular weight of the base or salt.
  • By keeping within these narrow ranges for in vitro dissolution rates, the present inventors have surprisingly found that although the present oral dosage forms give peak plasma levels of hydromorphone between 2 and 4 hours after administration, they still afford therapeutic levels of hydromorphone in vivo over at least a 12 hour period, and may therefore be used on a twice daily basis.
  • In order to obtain a controlled release drug dosage form having at least a 12 hour therapeutic effect, it is usual in the pharmaceutical art to produce a formulation that gives a peak plasma level of the drug between above 4-8 hours after administration (in a single dose study). The present inventors have surprisingly found that, in the case of hydromorphone, a peak plasma level at between 2-4 hours after administration gives at least 12 hours pain relief and, most surprisingly, that the pain relief obtained with such a formulation is greater than that achieved with formulations giving peak plasma levels (of hydromorphone) in the normal period of 1-2 hours after administration.
  • Furthermore, in the case of the present dosage form, therapeutic levels are generally achieved without concurrent side effects, such as nausea, vomiting, constipation and drowsiness, which are often associated with high blood levels of hydromorphone. There is also evidence to suggest that the use of the present dosage forms leads to a reduced risk of drug addiction.
  • A further advantage of the present composition, which releases hydromorphone at a rate that is independent of pH between 1.6 and 7.2, is that it avoids dose dumping upon oral administration. In other words, the hydromorphone is released evenly throughout the gastrointestinal tract.
  • The present oral dosage form may be presented, as for example, granules, spheroids or pellets in a capsule or in any other suitable solid form. Preferably, however, the oral dosage form is a tablet.
  • The present oral dosage form preferably contains between 1 and 100 mg, especially between 2 and 50 mg, most especially between 2 and 40mg, of hydromorphone hydrochloride. Alternatively the dosage form may contain molar equivalent amounts of other hydromorphone salts or of the hydromorphone base.
  • The present matrix may be any matrix that affords in vitro dissolution rates of hydromorphone within the narrow ranges required and that releases the hydromorphone in a pH independent manner. Preferably the matrix is a controlled release matrix, although normal release matrices having a coating that controls the release of the drug may be used. Suitable materials for inclusion in a controlled release matrix are
    • (a) Hydrophilic or hydrophobic polymers, such as gums, cellulose ethers, acrylic resins and protein derived materials. Of these polymers, the cellulose ethers, especially hydroxyalkylcelluloses and carboxyalkylcelluloses, are preferred. The oral dosage form may contain between 1% and 80% (by weight) of at least one hydrophilic or hydrophobic polymer.
    • (b) Digestible, long chain (C₈-C₅₀, expecially C₁₂-C₄₀), substituted or unsubstituted hydrocarbons, such as fatty acids, fatty alcohols, glyceryl esters of fatty acids, mineral and vegetable oils and waxes. Hydrocarbons having a melting point of between 25° and 90°C are preferred. Of these long chain hydrocarbon materials, fatty (aliphatic) alcohols are preferred. The oral dosage form may contain up to 60% (by weight) of at least one digestible, long chain hydrocarbon.
    • (c) Polyalkylene glycols. The oral dosage form may contain up to 60% (by weight) of at least one polyalkylene glycol.
  • One particularly suitable matrix comprises at least one water soluble hydroxyalkyl cellulose, at least one C₁₂-C₃₆, preferably C₁₄-C₂₂, aliphatic alcohol and, optionally, at least one polyalkylene glycol.
  • The at least one hydroxyalkyl cellulose is preferably a hydroxy (C₁ to C₆) alkyl cellulose, such as hydroxypropylcellulose, hydroxypropylmethylcellulose and, especially, hydroxyethyl cellulose. The amount of the at least one hydroxyalkyl cellulose in the present oral dosage form will be determined, inter alia, by the precise rate of hydromorphone release required. Preferably however, the oral dosage form contains between 5% and 25%, especially between 6.25% and 15% (by wt) of the at least one hydroxyalkyl cellulose.
  • The at least one aliphatic alcohol may be, for example, lauryl alcohol, myristyl alcohol or stearyl alcohol. In particularly preferred embodiments of the present oral dosage form, however, the at least one aliphatic alcohol is cetyl alcohol or cetostearyl alcohol. The amount of the at least one aliphatic alcohol in the present oral dosage form will be determined, as above, by the precise rate of hydromorphone release required. It will also depend on whether at least one polyalkylene glycol is present in or absent from the oral dosage form. In the absence of at least one polyalkylene glycol, the oral dosage form preferably contains between 20% and 50%, especially between 25% and 45% (by wt) of the at least one aliphatic alcohol. When at least one polyalkylene glycol is present in the oral dosage form, then the combined weight of the at least one aliphatic alcohol and the atleast one polyalkylene glycol preferably consitutes between 20% and 50%, especially between 25% and 45% (by wt) of the total dosage form.
  • In the present preferred dosage form, the ratio of the at least one hydroxyalkyl cellulose to the at least one aliphatic alcohol/polyalkylene glycol determines, to a considerable extent, the release rate of the hydromorphone from the formulation. A ratio of the at least one hydroxyalkyl cellulose to the at least one aliphatic alcohol/polyalkylene glycol of between 1:2 and 1:4 is preferred, with a ratio of between 1:3 and 1:4 being particularly preferred.
  • The at least one polyalkylene glycol may be, for example, polypropylene glycol or, which is preferred, polyethylene glycol. The number average molecular weight of the at least one polyalkylene glycol is preferred between 1000 and 15000 especially between 1500 and 12000.
  • Another suitable controlled release matrix would comprise an alkylcellulose (especially ethyl cellulose), a C₁₂ to C₃₆ aliphatic alcohol and, optionally, a polyalkylene glycol.
  • In addition to the above ingredients a controlled release matrix may also contain suitable quantities of other materials, e.g. diluents, lubricants, binders, granulating aids, colorants, flavorants and glidants that are conventional in the pharmaceutical art.
  • As an alternative to a controlled release matrix, the present matrix may be a normal release matrix having a coat that controls the release of the drug. In a particularly preferred embodiment of this aspect of the invention, the present dosage form comprises film coated spheroids containing active ingredient and non-water soluble spheronising agent. The term spheroid is known in the pharmaceutical art and means a spherical granule having a diameter of between 0.5mm and 2.5mm, especially between 0.5mm and 2mm.
  • The spheronising agent may be any pharmaceutically acceptable material that, together with the active ingredient, can be spheronised to form spheroids. Microcrystalline cellulose is preferred.
  • A suitable microcrystalline cellulose is, for example, the material sold as Avicel PH 101 (Trade Mark, FMC Corporation). According to a preferred aspect of the present invention, the film coated spheroids contain between 70% and 99% (by wt), especially between 80% and 95% (by wt), of the spheronising agent, especially microcrystalline cellulose.
  • In addition to the active ingredient and spheronising agent, the spheroids may also contain a binder. Suitable binders, such as low viscosity, water soluble polymers, will be well known to those skilled in the pharmaceutical art. However, water soluble hydroxy lower alkyl celluloses, such as hydroxy propyl cellulose, are preferred. Additionally (or alternatively) the spheroids may contain a water insoluble polymer, especially an acrylic polymer, an acrylic copolymer, such as a methacrylic acid-ethyl acrylate copolymer, or ethyl cellulose.
  • The spheroids are film coated with a material that permits release of the hydromorphone (or salt) at a controlled rate in an aqueous medium. The film coat is chosen so as to achieve in combination with the spheroids' other ingredients, the in-vitro release rate outlined above (between 12.5% and 42.5% (by wt) release after 1 hour, etc.).
  • The film coat will generally include a water insoluble material such as
    • (a) a wax, either alone or in admixture with a fatty alcohol,
    • (b) shellac or zein,
    • (c) a water insoluble cellulose, especially ethyl cellulose,
    • (d) a polymethacrylate, especially Eudragit (Trade Mark).
  • Preferably, the film coat comprises a mixture of the water insoluble material and a water soluble material. The ratio of water insoluble to water soluble material is determined by, amongst other factors, the release rate required and the solubility characteristics of the materials selected.
  • The water soluble material may be, for example, polyvinylpyrrolidone or, which is preferred, a water soluble cellulose, especially hydroxypropylmethyl cellulose.
  • Suitable combinations of water insoluble and water soluble materials for the film coat include shellac and polyvinylpyrrolidone or, which is preferred, ethyl cellulose and hydroxypropylmethyl cellulose
  • In order to facilitate the preparation of a solid, controlled release, oral dosage form according to this invention there is provided, in a further aspect of the present invention, a process for the preparation of a solid, controlled release, oral dosage form according to the present invention comprising incorporating hydromorphone or a salt thereof in a controlled release matrix. Incorporation in the matrix may be effected, for example, by
    • (a) forming granules comprising at least one water soluble hydroxyalkyl cellulose and hydromorphone or a hydromorphone salt,
    • (b) mixing the hydroxyalkyl cellulose containing granules with at least one C₁₂-C₃₆ aliphatic alcohol, and
    • (c) optionally, compressing and shaping the granules.
  • Preferably, the granules are formed by wet granulating the hydroxyalkyl cellulose/hydromorphone with water. In a particularly preferred embodiment of this process, the amount of water added during the wet granulation step is preferably between 1.5 and 5 times, especially between 1.75 and 3.5 times, the dry weight of the hydroxyalkylcellulose.
  • The present solid, controlled release, oral dosage form may also be prepared, in the form of film coated spheroids, by
    • (a) blending a mixture comprising hydromorphone or a hydromorphone salt and a non-water soluble spheronising agent,
    • (b) extruding the blended mixture to give an extrudate,
    • (c) spheronizing the extrudate until spheroids are formed, and
    • (d) coating the spheroids with a film coat.
  • The present solid, controlled release, oral dosage form and processes for its preparation will now be described by way of example only.
  • Example 1
  • Hydromorphone hydrochloride (4.0gm) was wet granulated with lactose monohydrate (167.0gm) and hydroxyethyl cellulose (40.0gm; Natrosel 250 HX, Trade Mark) and the granules were sieved through a 12 mesh screen. The granules were then dried in a Fluid Bed Dryer at 50°C and passed through a 16 mesh screen.
  • To the warmed hydromorphone containing granules was added molten cetostearyl alcohol (120.0gm) and the whole was mixed thoroughly. The mixture was allowed to cool in the air regranulated and sieved through a 16 mesh screen.
  • Purified Talc (6.0gm) and magnesium stearate (3.0gm) were then added and mixed with the granules. The granules were then compressed into 1000 tablet each containing,
    Figure imgb0001
    Figure imgb0002
  • Example 2
  • The procedure of Example 1 was followed, but with reduced quantities of cellulose and fatty alcohol, to give 1000 tablets each containing.
    Figure imgb0003
  • Example 3
  • Hydromorphone hydrochloride (4.0gm) was wet granulated with lactose monohydrate (30.0gm) hydroxyethyl cellulose (10.0gm; Natrosol 250 HX, Trade Mark) and methacrylic acid copolymer (30.0gm, Eudragit L-100-55; Trade Mark) and the granules were sieved through a 12 mesh screen. The granules were then dried in a Fluid Bed Dryer at 50°C and passed through a 16 mesh screen.
  • To the warmed hydromorphone containing granules was added molten cetostearyl alcohol (30.0gm) and the whole was mixed thoroughly. The mixture was allowed to cool in the air, regranulated and sieved through a 16 mesh screen.
  • The granules were then compressed into 1000 tablets each containing,
    Figure imgb0004
  • Example 4
  • Hydromorphone hydrochloride (50g) microcrystalline cellulose (Avicel PH101, 440g) and hydroxypropylmethyl cellulose (Methocel E15, 10g) were dry mixed. Water (350ml) was then added and the mixture was granulated. The granulated mass was extruded through a 1mm cylinder and the extrudate was spheronised. The resultant spheroids were dried at 60°C in a fluid bed drier. the moisture content of the dried spheroids was found to be 4.3% w/w (Karl-Fischer). The dried spheroids were then sieved and the sieve fraction between 1.0mm and 1.4mm was retained.
  • The spheroids were coated with a film coat, having the formulation given below, to a level of 15% w/w.
    Figure imgb0005
  • In Vitro Dissolution Studies
  • In vitro dissolution studies were conducted on tablets prepared as described in Example 1. The dissolution method was the USP Paddle Method described in US Pharmacopoeia XXI (1985). The paddle speed was 100 rpm, the temperature was 37°C and the medium was 900ml water.
  • Results are given in Table 1.
    Figure imgb0006
  • In vitro dissolution studies were conducted on tablets prepared as described in Example 1. The dissolution method was the USP Paddle Method described in US Pharmacopoeia XXI (1985). The paddle speed was 100rpm, the temperature was 37°C and the medium was an aqueous buffer (pH 6.5).
  • Results are given in Table 2.
    Figure imgb0007
  • In vitro dissolution studies were conducted on tablets prepared as described in Example 3. The dissolution method was the USP Paddle Method described in US Pharmacopoeia XXI (1985). The paddle speed was 100 rpm, the temperature was 37°C and the medium was 900 ml water.
  • Results are given in Table 3.
    Figure imgb0008
  • In vitro dissolution studies were conducted on tablets prepared as described in Example 1. The dissolution method was the USP Paddle Method described in US Pharmacopoeia XXI (1985). The paddle speed was 100rpm, the temperature was 37°C and the media were USP Buffers (pH 1.6, 6.5 and 7.2).
  • Results are given in Table 4.
    Figure imgb0009
  • Clinical Studies
    • A. A single dose, randomised, comparative, pharmacokinetic study was conducted on 4 subjects employing,
      i) A hydromorphone hydrochloride tablet prepared as described in Example 1, (a 4mg dose), and
      ii) A normal release hydromorphone hydrochloride tablet (Dilaudid; Trade Mark; a 4mg dose).
      Analysis of the plasma samples for hydromorphone was performed by a double antibody radioimmunoassay. Plasma was assayed by incubating first with ¹²⁵Iodohydromorphone and antimorphine antiserum (raised in goats against a 6-hemisuccinyl morphine-BSA conjugate), and subsequently with a solid phase bound antiserum suspension (Sac Cel, anti sheep/goat, Trade Mark). Following the addition of water the samples were centrifuged and the supernatant was removed. The radioactivity in the remaining pellet was counted on a multi-gamma counter for 60 seconds. Results are given in Table 5.
      Figure imgb0010
    • B. A single dose, randomised, comparative, pharmacokinetic study was conducted on 12 subjects employing.
      i) A hydromorphone hydrochloride tablet prepared as described in Example 1 (a 4mg dose), and
      ii) A normal release hydromorphone hydrochloride tablet (Dilaudid; Trade Mark; a 4mg dose).
      Analysis of the plasma samples for hydromorphone was performed by the radioimmunoassay described in study A. Results are given in Table 6.
      Figure imgb0011
    • C. A single dose, comparative, pharmacokinetic study was conducted on 24 subjects employing,
      (i) A hydromorphone hydrochloride tablet prepared as described in Example 1 (a 4mg dose) and,
      (ii) A normal release hydromorphone hydrochloride tablet (Dilaudid, Trade Mark, a 4 mg dose).
      Analysis of the plasma samples for hydromorphone was performed and the results are given in Table 7.
      Figure imgb0012

Claims (10)

1. A process for the preparation of a solid, controlled release, oral dosage form characterised by incorporating a therapeutically effective amount of hydromorphone or a salt thereof in a matrix wherein the dissolution rate in vitro of the dosage form when measured by the USP Paddle Method at 100rpm in 900ml aqueous buffer (pH between 1.6 and 7.2) at 37°C is between 12.5% and 42.5% (by weight) hydromorphone released after 1 hour, between 25% and 55% (by weight) hydromorphone released after 2 hours, between 45% and 75% (by weight) hydromorphone released after 4 hours and between 55% and 85% (by weight) hydromorphone released after 6 hours, the in vitro release rate being independent of pH between pH 1.6 and 7.2 and chosen such that the peak plasma level of hydromorphone obtained in vivo occurs between 2 and 4 hours after administration of the dosage form.
2. A process according to claim 1 characterised in that the in vitro dissolution rate is between 17.5% and 37.5% (by weight) hydromorphone released after 1 hour, between 30% and 50% (by weight) hydromorphone released after 2 hours, between 50% and 70% (by weight) hydromorphone released after 4 hours and between 60% and 80%, (by weight) hydromorphone released after 6 hours, preferably between 22.5% and 32.5% (by weight) hydromorphone released after 1 hour, between 35% and 45% (by weight) hydromorphone released after 2 hours, between 55% and 65% (by weight) hydromorphone released after 4 hours and between 65% and 75% (by weight) hydromorphone released after 6 hours.
3. A process according to either claim 1 or claim 2 characterised in that the matrix comprises a controlled release matrix comprising at least one water soluble hydroxyalkyl, preferably C₁ to C₆ alkyl, cellulose, at least one C₁₂ to C₃₆, preferably C₁₄ to C₂₂, aliphatic alcohol and, optionally at least one polyalkylene glycol, preferably polyethylene glycol.
4. A process according to any one of claims 1 to 3 characterised in that the at least one hydroxyalkyl cellulose comprises hydroxypropyl cellulose, hydroxypropylmethylcellulose or, preferably hydroxyethylcellulose.
5. A process according to either claim 3 or claim 4 characterised in that the dosage form contains between 5% and 25% (by weight), especially between 6.25% and 15% (by weight), of the at least one hydroxyalkylcellulose.
6. A process according to any one of claims 3 to 5 characterised in that the aliphatic alcohol comprises lauryl alcohol, myristyl alcohol, stearyl alcohol or preferably, cetyl alcohol or cetostearyl alcohol.
7. A process according to any one of claims 3 to 6 characterised in that the dosage form contains between 20% and 50%, preferably between 25% and 45% (by weight) of the at least one fatty alcohol or of the at least one fatty alcohol and the at least one polyalkylene glycol.
8. A process according to claim 1 characterised by
(a) wet granualting at least one water soluble hydroxyalkyl cellulose with hydromorphone or a salt thereof to form granules,
(b) mixing the hydroxyalkyl cellulose containing granules with at least one C₁₂-C₃₆ aliphatic alcohol, and
(c) optionally, compressing and shaping the granules
9. A process according to claim 8 characterised in that the at least one water soluble hydroxyalkyl cellulose and the hydromorphone or the salt thereof are wet granulated with water, the weight ratio of the water to the dry weight of the at least one water soluble hydroxyalkyl cellulose being between 1.5 to 1 and 5 to 1, especially between 1.75 and 1 and 3.5 to 1.
10. A process according to claim 1 characterised by blending a mixture comprising hydromorphone or a salt thereof and a non-water soluble spheronising agent, especially microcrystalline cellulose, extruding the blended mixture to give an extrudate, spheronising the extrudate until spheroids are formed and coating the spheroids with a film coat.
EP19870309333 1986-10-31 1987-10-22 Controlled release hydromorphone composition Expired - Lifetime EP0271193B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB8626098 1986-10-31
GB868626098A GB8626098D0 (en) 1986-10-31 1986-10-31 Controlled release hydromorphone composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT87309333T AT67933T (en) 1986-10-31 1987-10-22 Hydromorphone composition with a controlled drug release.

Publications (3)

Publication Number Publication Date
EP0271193A2 true EP0271193A2 (en) 1988-06-15
EP0271193A3 EP0271193A3 (en) 1988-07-13
EP0271193B1 EP0271193B1 (en) 1991-10-02

Family

ID=10606640

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19870309333 Expired - Lifetime EP0271193B1 (en) 1986-10-31 1987-10-22 Controlled release hydromorphone composition

Country Status (11)

Country Link
US (2) US4844909A (en)
EP (1) EP0271193B1 (en)
JP (1) JP2806385B2 (en)
AU (1) AU600765B2 (en)
CA (1) CA1297025C (en)
DE (1) DE3773468D1 (en)
DK (1) DK175139B1 (en)
ES (1) ES2038673T3 (en)
GB (2) GB8626098D0 (en)
IE (1) IE60495B1 (en)
ZA (1) ZA8708018B (en)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000889A1 (en) * 1991-07-08 1993-01-21 L.C. Pharchem Ltd. METHOD FOR THE PREPARATION OF PROLONGED-RELEASE ORAL PHARMACEUTICAL FORMS CONTAINING ACTIVE SUBSTANCES HAVING A SOLUBILITY DEPENDENT UPON THE pH VALUE
EP0557064A1 (en) * 1992-02-20 1993-08-25 Euroceltique S.A. Modified release formulation
EP0557065A1 (en) * 1992-02-20 1993-08-25 Euroceltique S.A. Spheroid formulation
EP0631781A1 (en) * 1993-07-01 1995-01-04 Euroceltique S.A. Opioid formulations having extended controlled release
GB2281204A (en) * 1993-07-27 1995-03-01 Euro Celtique Sa Sustained release morphine compositions
EP0647448A1 (en) * 1993-10-07 1995-04-12 Euroceltique S.A. Orally administrable opioid formulations having extended duration of effect
GB2284760A (en) * 1993-11-23 1995-06-21 Euro Celtique Sa Sustained release morphine compositions
EP0731694A1 (en) 1993-11-23 1996-09-18 Euroceltique S.A. Opioid formulations for treating pain
EP0785775A1 (en) 1994-11-04 1997-07-30 Euroceltique S.A. Melt-extruded orally administrable opioid formulations
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5849240A (en) * 1993-11-23 1998-12-15 Euro-Celtique, S.A. Method of preparing sustained release pharmaceutical compositions
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US6254887B1 (en) 1993-05-10 2001-07-03 Euro-Celtique S.A. Controlled release tramadol
US6399096B1 (en) 1995-09-22 2002-06-04 Euro-Celtique S.A. Pharmaceutical formulation
EP1258246A2 (en) * 1991-11-27 2002-11-20 Euro-Celtique S.A. Controlled release oxycodone compositions
EP0636370B2 (en) 1993-07-01 2004-01-02 Euro-Celtique S.A. Sustained release compositions containing morphine
EP1502591A2 (en) * 1993-06-23 2005-02-02 Euro-Celtique S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
WO2007149438A2 (en) * 2006-06-19 2007-12-27 Alpharma, Inc. Pharmaceutical compositions
EP2057984A1 (en) 2007-11-09 2009-05-13 Acino Pharma AG Retard tablets with hydromorphon
US7846476B2 (en) 2001-05-02 2010-12-07 Purdue Pharma L.P. Once-a-day oxycodone formulations
EP2446882A1 (en) 2010-10-28 2012-05-02 Acino Pharma AG Medicament with improved storage stability containing the active ingredient hydromorphone
US8557286B1 (en) 1999-04-22 2013-10-15 Euroceltique, S.A. Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix
US20140363516A1 (en) * 2011-12-21 2014-12-11 Hexal Aktiengesellschaft Multiple unit pellet tablet formulation comprising an opioid
US9034373B2 (en) 2006-03-16 2015-05-19 Euro-Celtique S.A. Pharmaceutical spheroids
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
US9655893B2 (en) 2001-05-02 2017-05-23 Purdue Pharma L.P. Once-a-day oxycodone formulations
US9669024B2 (en) 1999-10-29 2017-06-06 Purdue Pharma L.P. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813064D0 (en) * 1988-06-02 1988-07-06 Euro Celtique Sa Controlled release dosage forms having defined water content
US6056992A (en) * 1988-06-02 2000-05-02 Campbell Soup Company Encapsulated additives
EP0418597A3 (en) * 1989-09-21 1991-11-27 American Cyanamid Company Controlled release carbonic anhydrase inhibitor containing pharmaceutical compositions from spherical granules in capsule oral dosage unit form
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
AU2059297A (en) * 1996-03-12 1997-10-01 Alza Corporation Composition and dosage form comprising opioid antagonist
JPH1050306A (en) * 1996-07-31 1998-02-20 Toyota Autom Loom Works Ltd Manufacture of hydrogen storage alloy electrode
DE19710008A1 (en) * 1997-03-12 1998-09-17 Basf Ag Solid, at least two-phase preparation forms of an opioid sustained release Analgeticums
CA2314896C (en) * 1997-12-22 2005-09-13 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
DK1041987T3 (en) 1997-12-22 2006-08-21 Euro Celtique Sa An oral pharmaceutical dosage form comprising a combination of an opioid agonist and naltrexone
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
IL151057D0 (en) * 2000-02-08 2003-04-10 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
US6620431B1 (en) 2000-04-17 2003-09-16 Charles Signorino Shellac film coatings providing release at selected pH and method
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
AU7504301A (en) 2000-05-31 2001-12-11 Drugtech Corp Mineral supplement
KR100960200B1 (en) 2000-10-30 2010-05-27 유로-셀티크 소시에떼 아노뉨 Controlled release hydrocodone formulations
CA2446550C (en) 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
EP1406630A1 (en) * 2001-07-06 2004-04-14 Endo Pharmaceuticals Inc. Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
PL208484B1 (en) * 2001-07-06 2011-05-31 Penwest Pharmaceuticals Company Methods of making sustained release formulations of oxymorphone related applications
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
WO2003007802A2 (en) 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
EP1414451B1 (en) 2001-08-06 2009-05-20 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
JP2005523876A (en) * 2001-09-26 2005-08-11 ペンウェスト ファーマシューティカルズ カンパニー Opioid formulations potential for abuse is reduced
PE05272003A1 (en) * 2001-10-24 2003-07-26 Gruenenthal Chemie Pharmaceutical formulation with delayed release that contains 3- (3-dimethylamino-1-ethyl-2-methylpropyl) phenol or a pharmaceutically acceptable salt thereof and tablets for oral administration which contain
CN1298317C (en) * 2001-11-07 2007-02-07 斯索恩有限公司 Tamsulosin tablets
CN100411611C (en) 2002-04-05 2008-08-20 欧洲凯尔蒂克公司 Matrix for sustained, invariant and independent release of active compounds
EP2422775A3 (en) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
US20090162431A1 (en) * 2002-09-21 2009-06-25 Shuyi Zhang Sustained release formulations containing acetaminophen and tramadol
US20040110781A1 (en) * 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
WO2004054542A2 (en) * 2002-12-13 2004-07-01 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
CA2519556C (en) 2003-04-21 2011-01-18 Benjamin Oshlack Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
CA2930900C (en) 2003-10-02 2018-10-16 Jazz Pharmaceuticals International Limited Combinations of ziconotide and opioids for reducing pain
EP3228308A1 (en) * 2005-01-28 2017-10-11 Euro-Celtique S.A. Alcohol resistant dosage forms
AT419836T (en) * 2004-03-30 2009-01-15 Euro Celtique Sa Tamper-resistant dosage form with an adsorbent and an adverse agent
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP2415484B1 (en) * 2004-09-17 2014-06-18 Durect Corporation Sustained local anesthetic composition containing SAIB
KR20070115918A (en) * 2005-01-31 2007-12-06 교린 세이야꾸 가부시키 가이샤 Multiple unit oral sustained release preparation and process for production of the same
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
AU2006256851C1 (en) 2005-06-09 2010-07-15 Euro-Celtique S.A. Pharmaceutical compositions of a neuroactive steroid and uses thereof
US7884136B2 (en) 2005-06-27 2011-02-08 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
GB2431875A (en) * 2005-10-31 2007-05-09 Alza Corp Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
CN1957909B (en) 2005-10-31 2013-09-11 阿尔扎公司 Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US20080020032A1 (en) * 2006-07-21 2008-01-24 Michael Crowley Hydrophobic abuse deterrent delivery system for hydromorphone
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
EP2117521B1 (en) 2006-11-03 2012-06-27 Durect Corporation Transdermal delivery systems comprising bupivacaine
US20080220064A1 (en) * 2006-12-06 2008-09-11 Ramesh Ketkar Anant Extended release matrix formulations of morphine
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20090076135A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched hydromorphone
EP2219622A1 (en) * 2007-12-06 2010-08-25 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2224808A4 (en) * 2007-12-17 2013-11-27 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20090246276A1 (en) 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
PE04222011A1 (en) * 2008-07-07 2011-07-01 Euro Celtique Sa pharmaceutical composition comprising opioid antagonists
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
AR075735A1 (en) 2009-03-10 2011-04-20 Euro Celtique Sa Pharmaceutical compositions comprising immediate release oxycodone and naloxone. use
MX348361B (en) * 2009-12-17 2017-06-07 Cima Labs Inc Abuse-resistant formulations.
JP2013526523A (en) 2010-05-11 2013-06-24 シマ ラブス インク. Alcohol resistant sustained release oral dosage form comprising metoprolol
UA114887C2 (en) 2010-12-22 2017-08-28 Пюрдю Фарма Л.П. Encased tamper resistant controlled release dosage forms
NZ612996A (en) 2010-12-23 2015-05-29 Purdue Pharma Lp Tamper resistant solid oral dosage forms
US20130011444A1 (en) * 2011-07-09 2013-01-10 Syntrix Biosystems, Inc. Compositions and methods for overcoming resistance to tramadol
EP2606878A1 (en) * 2011-12-23 2013-06-26 Hexal AG Granulate and controlled release dosage forms comprising a hygroscopic active ingredient
US8946253B2 (en) 2012-04-17 2015-02-03 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
RU2665372C2 (en) * 2012-09-03 2018-08-29 Дайити Санкио Компани, Лимитед Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
JP6208261B2 (en) 2013-02-05 2017-10-04 パーデュー、ファーマ、リミテッド、パートナーシップPurdue Pharma L.P. Tampering resistant pharmaceutical preparations
CN105120659A (en) 2013-03-15 2015-12-02 度瑞公司 Compositions with a rheological modifier to reduce dissolution variability
US20140271896A1 (en) 2013-03-15 2014-09-18 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
JP2016525138A (en) 2013-07-23 2016-08-22 ユーロ−セルティーク エス.エイ. The combination of oxycodone and naloxone for use in the treatment of pain in patients suffering from diseases increase the risk for diseases and / or Enterobacteriaceae migration results in pain and intestinal Disconnect bio cis
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US3965256A (en) * 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
EP0156592A2 (en) * 1984-03-21 1985-10-02 American Home Products Corporation Substained release pharmaceutical capsules

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE427052B (en) * 1979-07-06 1983-02-28 Sunds Defibrator Apparatus for manufacturing mechanical pulp from lignocellulosic material
IE49324B1 (en) * 1979-12-19 1985-09-18 Euro Celtique Sa Controlled release compositions
US4320759A (en) * 1980-04-28 1982-03-23 Alza Corporation Dispenser with diffuser
US4622218A (en) * 1982-05-18 1986-11-11 University Of Florida Testicular-specific drug delivery
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US4558051A (en) * 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
IE55367B1 (en) * 1982-07-22 1990-08-29 Richardson Vicks Inc Improved analgesic and anti-inflammatory compositions comprising caffeine
US4576604A (en) * 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4599342A (en) * 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4678516A (en) * 1984-10-09 1987-07-07 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US3965256A (en) * 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
EP0156592A2 (en) * 1984-03-21 1985-10-02 American Home Products Corporation Substained release pharmaceutical capsules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Rote Liste", 1985, abstract no. 05002; "Dilaudid/dilaudid-atropin/-'schwach'/-'stark'" *
CHEMICAL ABSTRACTS, vol. 108, 1988, pages 326-327, abstract no. 26895u, Columbus, Ohio, US; P.V. PARAB et al.: "Biopharmaceutic parameters of hydromorphone and in vitro evaluation of ita tablet and suppository dosage forms", & PHARM. IND. 1987, 49(9), 951-6 *

Cited By (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000889A1 (en) * 1991-07-08 1993-01-21 L.C. Pharchem Ltd. METHOD FOR THE PREPARATION OF PROLONGED-RELEASE ORAL PHARMACEUTICAL FORMS CONTAINING ACTIVE SUBSTANCES HAVING A SOLUBILITY DEPENDENT UPON THE pH VALUE
EP0722730B2 (en) 1991-11-27 2013-08-07 The Purdue Pharma Company Controlled release oxycodone compositions
EP2106797A3 (en) * 1991-11-27 2009-11-04 Napp Pharmaceutical Holdings Limited Controlled release oxycodone compositions
EP2106797A2 (en) * 1991-11-27 2009-10-07 Napp Pharmaceutical Holdings Limited Controlled release oxycodone compositions
EP2106796A2 (en) * 1991-11-27 2009-10-07 Napp Pharmaceutical Holdings Limited Controlled release oxycodone compositions
EP2340833A2 (en) * 1991-11-27 2011-07-06 Napp Pharmaceutical Holdings Limited Controlled release oxycodone compositions
EP2243484A3 (en) * 1991-11-27 2012-01-11 Napp Pharmaceutical Holdings Limited Controlled release oxycodone compositions
EP2289517A3 (en) * 1991-11-27 2012-07-04 Napp Pharmaceutical Holdings Limited Controlled release oxycodone compositions
EP2340833A3 (en) * 1991-11-27 2012-09-12 Napp Pharmaceutical Holdings Limited Controlled release oxycodone compositions
CZ298499B6 (en) * 1991-11-27 2007-10-17 Euro-Celtique S.A. Solid oral controlled-release dosage form of oxycodone
EP1810679A3 (en) * 1991-11-27 2007-10-03 Napp Pharmaceutical Holdings Limited Controlled release oxycodone compositions
EP2106796A3 (en) * 1991-11-27 2009-11-04 Napp Pharmaceutical Holdings Limited Controlled release oxycodone compositions
EP1774969A3 (en) * 1991-11-27 2007-10-03 Napp Pharmaceutical Holdings Limited Controlled release oxycodone compositions
EP1774969A2 (en) * 1991-11-27 2007-04-18 Napp Pharmaceutical Holdings Limited Controlled release oxycodone compositions
EP1502592A1 (en) * 1991-11-27 2005-02-02 The Purdue Pharma Company Controlled release oxycodone compositions
EP1438959A1 (en) * 1991-11-27 2004-07-21 The Purdue Pharma Company Controlled release oxycodone compositions
EP1327446A1 (en) * 1991-11-27 2003-07-16 Euroceltique S.A. Controlled release oxycodone compositions
EP1327445A1 (en) * 1991-11-27 2003-07-16 Euroceltique S.A. Controlled release oxycodone compositions
EP1325746A1 (en) * 1991-11-27 2003-07-09 Euroceltique S.A. Controlled release oxycodone compositions
EP1258246A3 (en) * 1991-11-27 2003-01-08 Euro-Celtique S.A. Controlled release oxycodone compositions
EP1258246A2 (en) * 1991-11-27 2002-11-20 Euro-Celtique S.A. Controlled release oxycodone compositions
EP2289517A2 (en) * 1991-11-27 2011-03-02 Napp Pharmaceutical Holdings Limited Controlled release oxycodone compositions
US6294195B1 (en) 1991-12-24 2001-09-25 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US7270831B2 (en) 1991-12-24 2007-09-18 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US6572885B2 (en) 1991-12-24 2003-06-03 Euro-Celtique, S.A. Orally administrable opioid formulations having extended duration of effect
EP0557065A1 (en) * 1992-02-20 1993-08-25 Euroceltique S.A. Spheroid formulation
EP0557064A1 (en) * 1992-02-20 1993-08-25 Euroceltique S.A. Modified release formulation
US6326027B1 (en) 1993-05-10 2001-12-04 Euro-Celtique S.A. Controlled release formulation
US6254887B1 (en) 1993-05-10 2001-07-03 Euro-Celtique S.A. Controlled release tramadol
EP1504757A2 (en) * 1993-06-23 2005-02-09 Euro-Celtique S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
EP1502591A2 (en) * 1993-06-23 2005-02-02 Euro-Celtique S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
EP1504757A3 (en) * 1993-06-23 2006-04-12 Euro-Celtique S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
EP1502591A3 (en) * 1993-06-23 2006-02-08 Euro-Celtique S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
EP1430897A2 (en) * 1993-07-01 2004-06-23 Euro-Celtique S.A. Opioid formulations having extended controlled release
CN1292742C (en) * 1993-07-01 2007-01-03 欧罗赛铁克股份有限公司 Opioid formulations having extended controlled release
EP0636370B2 (en) 1993-07-01 2004-01-02 Euro-Celtique S.A. Sustained release compositions containing morphine
EP1243269A2 (en) * 1993-07-01 2002-09-25 Euro-Celtique S.A. Opioid formulations having extended controlled release
EP0631781A1 (en) * 1993-07-01 1995-01-04 Euroceltique S.A. Opioid formulations having extended controlled release
US6103261A (en) * 1993-07-01 2000-08-15 Purdue Pharma Lp Opioid formulations having extended controlled release
EP1243269A3 (en) * 1993-07-01 2003-01-08 Euro-Celtique S.A. Opioid formulations having extended controlled release
EP2263673A1 (en) * 1993-07-01 2010-12-22 Euro-Celtique S.A. Opioid formulations having extended controlled release
EP1430897A3 (en) * 1993-07-01 2004-07-14 Euro-Celtique S.A. Opioid formulations having extended controlled release
US6143328A (en) * 1993-07-27 2000-11-07 Euro-Celtique, S.A. Sustained release compositions and a method of preparing pharmaceutical compositions
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
GB2281204A (en) * 1993-07-27 1995-03-01 Euro Celtique Sa Sustained release morphine compositions
EP1442745A1 (en) * 1993-10-07 2004-08-04 Euro-Celtique Orally administrable opioid formulations having extended duration of effect
EP2036558A3 (en) * 1993-10-07 2010-04-28 Euro-Celtique S.A. Orally administrable opioid formulations having extended duration of effect
EP0647448A1 (en) * 1993-10-07 1995-04-12 Euroceltique S.A. Orally administrable opioid formulations having extended duration of effect
EP2036558A2 (en) * 1993-10-07 2009-03-18 Euro-Celtique S.A. Orally administrable opioid formulations having extended duration of effect
US5849240A (en) * 1993-11-23 1998-12-15 Euro-Celtique, S.A. Method of preparing sustained release pharmaceutical compositions
EP0731694A1 (en) 1993-11-23 1996-09-18 Euroceltique S.A. Opioid formulations for treating pain
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5672360A (en) * 1993-11-23 1997-09-30 Purdue Pharma, L.P. Method of treating pain by administering 24 hour oral opioid formulations
GB2284760A (en) * 1993-11-23 1995-06-21 Euro Celtique Sa Sustained release morphine compositions
GB2284760B (en) * 1993-11-23 1998-06-24 Euro Celtique Sa A method of preparing pharmaceutical compositions by melt pelletisation
EP0731694B2 (en) 1993-11-23 2005-09-07 Euro-Celtique S.A. Opioid formulations for treating pain
US6162467A (en) * 1993-11-23 2000-12-19 Euro-Celtique, S.A. Sustained release compositions and a method of preparing pharmaceutical compositions
US5965163A (en) * 1993-11-23 1999-10-12 Euro-Celtique, S.A. Substained release compositions and a method of preparing pharmaceutical compositions
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
EP0785775B2 (en) 1994-11-04 2012-12-05 Euro-Celtique S.A. Melt-extruded orally administrable opioid formulations
EP0785775A1 (en) 1994-11-04 1997-07-30 Euroceltique S.A. Melt-extruded orally administrable opioid formulations
US6743442B2 (en) 1994-11-04 2004-06-01 Euro-Celtique, S.A. Melt-extruded orally administrable opioid formulations
US6399096B1 (en) 1995-09-22 2002-06-04 Euro-Celtique S.A. Pharmaceutical formulation
US8506998B2 (en) 1995-09-22 2013-08-13 Euro-Celtique S.A. Pharmaceutical formulation
US8557286B1 (en) 1999-04-22 2013-10-15 Euroceltique, S.A. Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix
US10076516B2 (en) 1999-10-29 2018-09-18 Purdue Pharma L.P. Methods of manufacturing oral dosage forms
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9669024B2 (en) 1999-10-29 2017-06-06 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9675611B1 (en) 1999-10-29 2017-06-13 Purdue Pharma L.P. Methods of providing analgesia
US9669022B2 (en) 1999-10-29 2017-06-06 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9655894B2 (en) 2001-05-02 2017-05-23 Purdue Pharma L.P. Once-A day oxycodone formulations
US9655893B2 (en) 2001-05-02 2017-05-23 Purdue Pharma L.P. Once-a-day oxycodone formulations
US9750736B2 (en) 2001-05-02 2017-09-05 Purdue Pharma L.P. Oxycodone formulations
US7846476B2 (en) 2001-05-02 2010-12-07 Purdue Pharma L.P. Once-a-day oxycodone formulations
US9034373B2 (en) 2006-03-16 2015-05-19 Euro-Celtique S.A. Pharmaceutical spheroids
EP2484346A1 (en) * 2006-06-19 2012-08-08 Alpharma Pharmaceuticals, LLC Pharmaceutical compositions
EP2526932A1 (en) * 2006-06-19 2012-11-28 Alpharma Pharmaceuticals, LLC Pharmaceutical composition
WO2007149438A3 (en) * 2006-06-19 2009-09-24 Alpharma, Inc. Pharmaceutical compositions
WO2007149438A2 (en) * 2006-06-19 2007-12-27 Alpharma, Inc. Pharmaceutical compositions
EP2719378A1 (en) * 2006-06-19 2014-04-16 Alpharma Pharmaceuticals LLC Pharmaceutical compositions
EP2057984A1 (en) 2007-11-09 2009-05-13 Acino Pharma AG Retard tablets with hydromorphon
WO2009059701A2 (en) 2007-11-09 2009-05-14 Acino Pharma Ag Sustained release tablets with hydromorphone
EP2425822A1 (en) 2007-11-09 2012-03-07 Acino Pharma AG Sustained release tablets with hydromorphone
WO2009059701A3 (en) * 2007-11-09 2009-07-16 Acino Pharma Ag Sustained release tablets with hydromorphone
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
WO2012055708A1 (en) 2010-10-28 2012-05-03 Acino Pharma Ag Medicinal product comprising hydromorphone, with improved shelf-life
EP2446882A1 (en) 2010-10-28 2012-05-02 Acino Pharma AG Medicament with improved storage stability containing the active ingredient hydromorphone
US20140363516A1 (en) * 2011-12-21 2014-12-11 Hexal Aktiengesellschaft Multiple unit pellet tablet formulation comprising an opioid

Also Published As

Publication number Publication date
IE872924L (en) 1988-04-30
AU600765B2 (en) 1990-08-23
GB2196848B (en) 1990-11-14
AU8052487A (en) 1988-05-05
GB2196848A (en) 1988-05-11
EP0271193A3 (en) 1988-07-13
IE60495B1 (en) 1994-07-27
CA1297025C (en) 1992-03-10
US4990341A (en) 1991-02-05
ES2038673T3 (en) 1993-08-01
US4844909A (en) 1989-07-04
ZA8708018B (en) 1988-04-29
GB8724705D0 (en) 1987-11-25
DE3773468D1 (en) 1991-11-07
DK568687D0 (en) 1987-10-30
DK568687A (en) 1988-05-01
EP0271193B1 (en) 1991-10-02
JPS63122623A (en) 1988-05-26
JP2806385B2 (en) 1998-09-30
GB8626098D0 (en) 1986-12-03
DK175139B1 (en) 2004-06-14

Similar Documents

Publication Publication Date Title
KR890004688B1 (en) Sustained release pharmaceutical carrier compositions
US5811126A (en) Controlled release matrix for pharmaceuticals
US5445829A (en) Extended release pharmaceutical formulations
AU722358B2 (en) Sustained release compositions and a method of preparing pharmaceutical compositions
CN1029935C (en) Pharmaceutical preparation and process for same
US4309404A (en) Sustained release pharmaceutical compositions
KR100205276B1 (en) Sustained-release tablet
CA1304294C (en) Pharmaceutical preparations with extended release
US4427648A (en) Dipyridamole-containing pharmaceutical form
US5403593A (en) Melt granulated compositions for preparing sustained release dosage forms
CA2306333C (en) Oral morphine multiparticulate formulation
ES2282757T3 (en) Formulations orally administrable opioid extruded fusion.
CN1096862C (en) Controlled-release dosage form of azithromycin
US5670172A (en) Pharmaceutical spheroid formulation
CN1309374C (en) Improved rapidly disintegratable multiparticulate tablet
JP4405372B2 (en) Opioid formulation with extended release inhibitory
US5912013A (en) Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
DK200000364U3 (en) Oxycodenpræparater controlled release
US5188840A (en) Slow-release pharmaceutical agent
US5472704A (en) Pharmaceutical controlled-release composition with bioadhesive properties
EP0142561A1 (en) Long-acting nifedipine preparation
US20080044482A1 (en) Orally administrable opioid formulations having extended duration of effect
US6576260B2 (en) Sustained-release form of administration containing tramadol saccharinate
KR100958045B1 (en) Pharmaceutical containing 3-3-dimethylamino-1-ethyl-2-methyl-propylphenol and providing delayed release of the active ingredient
JP3825991B2 (en) Sustained release oral opioid formulation

Legal Events

Date Code Title Description
AK Designated contracting states:

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB IT LI NL SE

AK Designated contracting states:

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB IT LI NL SE

17P Request for examination filed

Effective date: 19880819

17Q First examination report

Effective date: 19900314

REF Corresponds to:

Ref document number: 67933

Country of ref document: AT

Date of ref document: 19911015

Kind code of ref document: T

AK Designated contracting states:

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB IT LI NL SE

ITF It: translation for a ep patent filed

Owner name: BUGNION S.P.A.

REF Corresponds to:

Ref document number: 3773468

Country of ref document: DE

Date of ref document: 19911107

ET Fr: translation filed
26 Opposition filed

Opponent name: BASF AKTIENGESELLSCHAFT, LUDWIGSHAFEN

Effective date: 19920701

NLR1 Nl: opposition has been filed with the epo

Opponent name: BASF AKTIENGESELLSCHAFT

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2038673

Country of ref document: ES

Kind code of ref document: T3

EAL Se: european patent in force in sweden

Ref document number: 87309333.0

27O Opposition rejected

Effective date: 19970116

NLR2 Nl: decision of opposition
REG Reference to a national code

Ref country code: FR

Ref legal event code: CP

Free format text: PRODUCT NAME: HYDROMORPHONE; HYDROCHLORHYDE; NAT. REGISTRATION NO/DATE: NL20412 19970219; FIRST REGISTRATION: IE - PA114/73/1 19930302

Spc suppl protection certif: 97C0116

Filing date: 19970819

REG Reference to a national code

Ref country code: FR

Ref legal event code: CR

Free format text: FRCR 97C0116, 19970819

REG Reference to a national code

Ref country code: FR

Ref legal event code: CP

REG Reference to a national code

Ref country code: FR

Ref legal event code: CY

Free format text: FRCY 97C0116, 19970819, EXPIRES: 20080302

REG Reference to a national code

Ref country code: FR

Ref legal event code: CL

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Postgrant: annual fees paid to national office

Ref country code: AT

Payment date: 20060907

Year of fee payment: 20

PGFP Postgrant: annual fees paid to national office

Ref country code: FR

Payment date: 20060911

Year of fee payment: 20

PGFP Postgrant: annual fees paid to national office

Ref country code: GB

Payment date: 20060914

Year of fee payment: 20

PGFP Postgrant: annual fees paid to national office

Ref country code: CH

Payment date: 20060918

Year of fee payment: 20

PGFP Postgrant: annual fees paid to national office

Ref country code: NL

Payment date: 20060921

Year of fee payment: 20

PGFP Postgrant: annual fees paid to national office

Ref country code: DE

Payment date: 20060925

Year of fee payment: 20

PGFP Postgrant: annual fees paid to national office

Ref country code: ES

Payment date: 20061004

Year of fee payment: 20

PGFP Postgrant: annual fees paid to national office

Ref country code: BE

Payment date: 20061006

Year of fee payment: 20

PGFP Postgrant: annual fees paid to national office

Ref country code: IT

Payment date: 20061031

Year of fee payment: 20

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV7 Nl: lapsed due to reaching the maximum lifetime of a patent

Effective date: 20071022

BE20 Be: patent expired

Owner name: S.A. *EUROCELTIQUE

Effective date: 20071022

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20071023

PGFP Postgrant: annual fees paid to national office

Ref country code: SE

Payment date: 20060919

Year of fee payment: 20

PG25 Lapsed in a contracting state announced via postgrant inform. from nat. office to epo

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20071022

PG25 Lapsed in a contracting state announced via postgrant inform. from nat. office to epo

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20071021

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20071023